Loading...
XSHE000919
Market cap529mUSD
Jan 10, Last price  
6.30CNY
1D
-2.17%
1Q
-2.93%
Jan 2017
-53.44%
Name

Jinling Pharmaceutical Co.

Chart & Performance

D1W1MN
XSHE:000919 chart
P/E
38.98
P/S
1.39
EPS
0.16
Div Yield, %
1.32%
Shrs. gr., 5y
—
Rev. gr., 5y
-0.79%
Revenues
2.79b
+4.30%
1,001,752,7861,235,800,2831,375,734,3131,548,968,8911,788,881,9641,966,705,7662,161,139,2872,257,022,7772,304,934,2202,605,713,7822,771,942,2863,221,375,3853,578,652,7743,191,811,8632,899,079,0222,534,920,5392,503,732,3742,808,754,8762,670,968,0382,785,738,409
Net income
100m
-5.35%
112,354,531157,848,357201,827,473307,465,69482,598,435220,957,624192,731,459165,201,943143,556,314155,890,349197,184,453208,109,272180,151,292137,126,464241,786,876145,319,43993,657,703120,625,946105,281,85499,652,601
CFO
159m
-39.01%
159,807,997109,293,829138,503,706118,063,748305,263,648188,410,396177,809,117172,822,179232,116,926271,208,292299,891,714212,449,64196,149,992443,109,707433,825,968465,847,095311,464,432292,026,282260,590,694158,923,988
Dividend
May 31, 20240.1 CNY/sh
Earnings
May 21, 2025

Profile

Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China. The company offers Mailuoning injection for the treatment of thrombo-occlusive vasculitis, arteriosclerotic occlusive disease, cerebral thrombosis and sequelae, multiple arteritis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; and lentinan injection for treatment of malignant tumors. It also provides medical health care services. Jinling Pharmaceutical Company Limited is based in Nanjing, China.
URL
http://www.jlyy1999.com/
IPO date
Nov 18, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,785,738
4.30%
2,670,968
-4.91%
Cost of revenue
2,420,247
2,377,255
Unusual Expense (Income)
NOPBT
365,492
293,713
NOPBT Margin
13.12%
11.00%
Operating Taxes
11,234
13,904
Tax Rate
3.07%
4.73%
NOPAT
354,258
279,809
Net income
99,653
-5.35%
105,282
-12.72%
Dividends
(51,156)
(50,400)
Dividend yield
1.29%
1.29%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
3,010
Long-term debt
5,099
4,579
Deferred revenue
468
627
Other long-term liabilities
1
1
Net debt
(1,791,248)
(1,752,448)
Cash flow
Cash from operating activities
158,924
260,591
CAPEX
(186,251)
Cash from investing activities
(370,155)
Cash from financing activities
(43,269)
FCF
519,639
90,504
Balance
Cash
1,512,261
1,587,374
Long term investments
284,086
172,663
Excess cash
1,657,060
1,626,489
Stockholders' equity
2,822,309
3,148,713
Invested Capital
2,030,903
1,948,190
ROIC
17.81%
15.14%
ROCE
9.85%
8.11%
EV
Common stock shares outstanding
504,000
504,000
Price
7.87
1.29%
7.77
1.57%
Market cap
3,966,480
1.29%
3,916,080
1.57%
EV
2,817,566
2,796,509
EBITDA
496,752
418,053
EV/EBITDA
5.67
6.69
Interest
1,367
256
Interest/NOPBT
0.37%
0.09%